A CITF-funded study published in The Lancet Gastroenterology & Hepatology by Drs. Gilaad Kaplan (University of Calgary) and Sasha Bernatsky (McGill University) on behalf of the STOP COVID-19 in IBD Research Group, showed a robust antibody response was achieved in individuals with IBD after the fourth dose of COVID-19 vaccine, similar in magnitude to that which followed the third dose.
A CITF-funded study, published in Transplant Cell Therapy, from Dr. Deepali Kumar’s team (University of Toronto) shows that a third dose of COVID-19 vaccine resulted in stronger humoral and cell-mediated immunity in allogeneic stem cell transplant (Allo-SCT) recipients, when compared to the initial two-dose vaccine regimen.
A CITF-funded study published in AIDS and led by Drs. Aslam Anis (University of British Columbia) and Ann Burchell (University of Toronto) on behalf of the COVAXHIV study team, highlighted that – prior to Omicron – two doses of COVID-19 vaccines offered substantial protection against hospitalization and death, and even symptomatic illness, in people living with HIV (PLWH).
A research letter by CITF-funded Drs. Mel Krajden (BC Centre for Disease Control), Matthew Oliver (University of Toronto), and Adeera Levin (University of British Columbia), published in Kidney International, investigated the effectiveness of COVID-19 vaccines among non-dialysis dependent patients with chronic kidney disease (CKD).
A CITF-funded study published in Nature Communications by Drs. Deepali Kumar and Atul Humar (University Health Network, Toronto), reported that partially and fully vaccinated transplant recipients who were infected with Omicron (the BA.1 variant) have BA.1-specific immune responses comparable to triple vaccinated individuals with normal immune systems.
A preprint, not yet peer-reviewed, CITF-funded study found that only 45% of kidney transplant recipients (KTRs) developed Omicron-specific neutralizing antibodies one month following a third vaccine dose.
In a paper now published in the Journal of Infectious Diseases, Drs. Zabrina Brumme and Mark Brockman from Simon Fraser University and the BC Centre for Excellence in HIV/AIDS, and members of the Canadian HIV Trials Network, led by Dr. Aslam Anis from the University of British Columbia, demonstrate that responses to COVID-19 vaccines in people living with HIV (PLWH) are similar to those without HIV.
Drs. Matthew Oliver (University of Toronto) and Peter Blake (Western University) published an editorial in the Clinical Journal of the American Society of Nephrology assessing the clinical impact of COVID-19 vaccines on protecting people living with chronic kidney disease (CKD).
Over 99% of a subset of individuals living with inflammatory bowel disease (IBD) mounted an antibody response against the spike protein after their third vaccine dose, found a letter published in Gut, under the leadership of Dr. Gil Kaplan (University of Calgary) and co-authored by Dr. Sasha Bernatsky (Research Institute of the McGill University Health Centre), who are funded by CITF.
A paper now published in JCI Insight by CITF-funded researchers Drs. Anne-Claude Gingras, Tania Watts, and Vinod Chandran of the University of Toronto provides evidence of the need for a third dose of mRNA vaccine in patients with immune-mediated inflammatory diseases (IMID).